Endocrinology › Obesity

GLP-1 Agonist & Anti-Obesity Medication Benefit-Risk Analysis for Obesity

The anti-obesity drug landscape is transforming with GLP-1 receptor agonists and multi-agonist therapies. ArcaScience provides comprehensive BRA across semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), survodutide, orforglipron (oral GLP-1), retatrutide (GLP-1/GIP/glucagon triple agonist), and CagriSema (semaglutide + cagrilintide).

See Platform Request Demo

890M+

Adults with obesity worldwide

4,500+

Obesity/GLP-1 clinical trials analyzed

$100B+

Projected anti-obesity drug market by 2030

15+

GLP-1/GIP/glucagon agents in late-stage development

Disease Overview

Why GLP-1 Agonist Therapy Demands Specialized BRA

The rapid proliferation of GLP-1 receptor agonists and next-generation multi-agonist therapies for obesity introduces a complex safety landscape spanning gastrointestinal, thyroid, psychiatric, and metabolic domains, requiring specialized benefit-risk frameworks that account for chronic use in a predominantly healthy population.

GI & Pancreatobiliary Safety

Nausea, vomiting, and diarrhea affect 40-50% of patients during dose titration, driving significant discontinuation rates. Pancreatitis signals remain an ongoing debate across the GLP-1 class, with gallbladder events (cholelithiasis) emerging as a dose-dependent risk. Gastroparesis, delayed gastric emptying, ileus concerns, and emerging intestinal obstruction signals require continuous post-marketing surveillance and proactive BRA.

Thyroid & Cancer Risk

All GLP-1 receptor agonists carry a boxed warning for medullary thyroid carcinoma based on rodent C-cell tumor findings. Long-term cancer surveillance requirements across the class remain uncertain, with ongoing epidemiological studies evaluating thyroid cancer incidence in exposed populations. Thyroid monitoring protocols must be standardized across GLP-1 and dual/triple agonist therapies as the treated population expands dramatically.

Psychiatric & Suicidality Signals

The EMA launched a formal review of suicidal ideation reports associated with GLP-1 receptor agonists. Beyond psychiatric signals, rapid weight loss raises concerns about muscle mass loss and sarcopenia, bone mineral density reduction, and the well-documented phenomenon of weight regain upon discontinuation. The risk-benefit calculus must weigh metabolic benefits against these long-term body composition and psychological effects.

Platform Capabilities

How ArcaScience Addresses Obesity BRA

Our modules are configured with GLP-1 agonist and anti-obesity medication data, metabolic safety detection models, and regulatory templates for obesity pharmacotherapy submissions.

Data Intelligence

Obesity & GLP-1 Trial Data

4,500+ obesity and GLP-1 clinical trials including STEP, SURMOUNT, and OASIS program data. Real-world insurance claims from 50M+ patients capturing treatment patterns, discontinuation rates, and long-term outcomes. Comprehensive FAERS GLP-1 safety database covering all approved incretin-based therapies with pancreatobiliary, thyroid, and psychiatric event coding.

Explore Data Engine →

Decision Intelligence

Metabolic Safety AI Models

AI models for pancreatitis signal differentiation from background obesity comorbidity rates, thyroid C-cell risk modeling across GLP-1/GIP/glucagon receptor agonist mechanisms, psychiatric event detection including suicidal ideation signal evaluation, and body composition change prediction modeling lean mass loss and bone density effects during rapid weight reduction.

Explore AI Models →

Automated Outputs

Obesity Regulatory Outputs

PSURs for the GLP-1 agonist class with pancreatobiliary, thyroid, and psychiatric safety sections. REMS documentation if required by regulatory authorities. Comparative BRA reports across semaglutide, tirzepatide, and survodutide for differentiation strategies. Pediatric obesity submission packages supporting ages 12+ with growth and development safety data integration.

Explore Outputs →

Obesity Intelligence

Platform Performance in Obesity

12,500,000,000+

Metabolic pharmacovigilance data points

69%

Faster pancreatobiliary signal detection

Obesity-specific AI models deployed

Anti-obesity regulatory submissions supported

Case Evidence — Obesity

GLP-1 Agonist Class-Wide Pancreatobiliary Safety Assessment

Challenge

A pharma company needed to differentiate true pancreatitis signals from confounded obesity comorbidities across their GLP-1 agonist portfolio, while simultaneously characterizing gallbladder events (cholelithiasis, cholecystitis) that were emerging as a dose-dependent class effect in post-marketing data.

Result

ArcaScience's AI models enabled 3.9x faster gallbladder event characterization by integrating real-world claims data with clinical trial adverse event reports, and achieved a 47% reduction in confounded pancreatitis false positives by adjusting for obesity-related background pancreatitis rates and gallstone disease prevalence.

3.9x

Faster gallbladder event characterization

47%

Reduction in confounded pancreatitis false positives

View All Case Studies →

Separating real pancreatitis signals from the noise of obesity-related comorbidities was our biggest pharmacovigilance challenge. ArcaScience's background rate adjustment models gave us the confidence to present clean, defensible data to regulators and fundamentally changed how we approach GLP-1 class-wide safety assessments.

SVP of Metabolic Disease Safety

Global Pharma Company

Frequently Asked Questions

Obesity & GLP-1 Agonist BRA

Our platform integrates real-world obesity population background rates for pancreatitis, gallstone disease, and biliary events to establish expected incidence baselines. AI models then apply confounding adjustment algorithms that account for BMI, diabetes status, alcohol use, and hypertriglyceridemia to isolate drug-attributable pancreatitis signals from obesity-related background noise. This approach has reduced false positive pancreatitis signals by 47% compared to standard disproportionality methods.

Yes. ArcaScience aggregates medullary thyroid carcinoma (MTC) and thyroid cancer reports across all approved GLP-1 receptor agonists, GIP/GLP-1 dual agonists, and emerging triple agonists. Our models incorporate rodent C-cell tumor data, human epidemiological studies, FAERS thyroid event reports, and cancer registry linkage data to provide class-level and molecule-specific thyroid cancer risk assessments. The platform also tracks ongoing regulatory guidance evolution from the FDA and EMA regarding long-term thyroid monitoring requirements.

Following the EMA's formal review of suicidal ideation reports with GLP-1 receptor agonists, our platform provides dedicated psychiatric event surveillance across the entire incretin class. AI models analyze spontaneous reports, clinical trial psychiatric adverse event data, and patient-reported outcome measures to assess causality versus confounding from pre-existing depression and body image disorders common in the obesity population. The platform generates regulatory-ready signal evaluation reports that meet PRAC and FDA Sentinel System standards.

Yes. With semaglutide and other GLP-1 agonists gaining approval for adolescent obesity (ages 12+), our platform provides pediatric-specific BRA frameworks that account for growth and development considerations, bone mineral density accrual during puberty, hormonal development effects, and the unique risk-benefit profile of chronic weight management therapy in a growing population. Submission packages integrate pediatric safety data with adult extrapolation models as required by FDA and EMA pediatric investigation plans.

See ArcaScience Applied to Obesity

Request a demonstration focused on obesity and GLP-1 agonist BRA. Our metabolic disease scientists will present pancreatobiliary signal differentiation models, thyroid cancer risk assessments, and anti-obesity regulatory submission frameworks.

Request Obesity Briefing Explore the Platform →